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SUMMARY
Recombinant NcPDI(recNcPDI), NcROP2(recNcROP2), and NcMAG1(recNcMAG1) were expressed in Escherichia
coli and puriﬁed, and evaluated as potential vaccine candidates by employing the C57Bl/6 mouse cerebral infection model.
Intraperitoneal application of these proteins suspended in saponin adjuvants lead to protection against disease in 50% and
70% of mice vaccinated with recNcMAG1 and recNcROP2, respectively, while only 20% of mice vaccinated with
recNcPDI remained without clinical signs. In contrast, a 90% protection rate was achieved following intra-nasal vacci-
nation with recNcPDI emulsiﬁed in cholera toxin. Only 1 mouse vaccinated intra-nasally with recNcMAG1 survived the
challenge infection, and protection achieved with intra-nasally applied recNcROP2 was at 60%. Determination of cerebral
parasite burdens by real-time PCR showed that these were signiﬁcantly reduced only in recNcROP2-vaccinated animals
(following intraperitoneal and intra-nasal application) and in recNcPDI-vaccinated mice (intra-nasal application only).
Quantiﬁcation of viable tachyzoites in brain tissue of intra-nasally vaccinated mice showed that immunization with
recNcPDI resulted in signiﬁcantly decreased numbers of live parasites. These data show that, besides the nature of the
antigen, the protective eﬀect of vaccination also depends largely on the route of antigen delivery. In the case of recNcPDI,
the intra-nasal route provides a platform to generate a highly protective immune response.
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INTRODUCTION
Neospora caninum is an apicomplexan parasite that
causes abortion and stillbirth in cattle and neuro-
muscular disease in dogs. Many other species can
also be aﬀected. The parasite has emerged as a sig-
niﬁcant veterinary public health problem, since it has
been shown to represent the most important abor-
tion-causing pathogen in bovines, responsible for
economic losses to the cattle industry worldwide
(McAllister et al. 1998; Gondim, 2004; Dubey et al.
2007). Protection of fetal death in cattle has been
achieved experimentally by immunization of dams
with live N. caninum tachyzoites (Williams et al.
2007). However, at the present time, there is no non-
live vaccine capable of inducing complete protective
immunity against neosporosis in cattle.
Mice have been widely used as laboratory models
for proof-of-concept studies involving vaccine can-
didates, in spite of the fact that murines and bovines
exhibit somewhat diﬀerent immunological charac-
teristics (reviewed by Hemphill et al. 2006; Innes,
2007; Innes and Mattsson, 2007). Infection with
killed tachyzoite lysate prevents foetal infection in
mice (Liddell et al. 1999), but not in cattle. A com-
mercialized vaccine, consisting of tachyzoite lysate
(NeoguardTM), is currently marketed in the US, but
eﬃcacy data are diﬃcult to interpret (Williams and
Trees, 2006; Innes and Vermeulen, 2006).
To date, the major portion of antigens that have
been investigated as subunit vaccine candidates are
involved in tachyzoite-host cell interactions, and are
localized either on the surface of tachyzoites, or with-
in secretory organelles such micronemes, rhoptries
and dense granules (reviewed by Hemphill et al.
2006). Various strategies have been used to enhance
the post-vaccination immune response, such as ap-
plication of multiple recombinant antigens in one
shot (Cho et al. 2005; Ellis et al. 2008), diﬀerent
adjuvants and dosages, various formulations and
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diﬀerent routes of administration (Innes and
Mattsson, 2007).
For non-live vaccines such as recombinant anti-
gens, the classical application routes are either intra-
peritoneal (i.p.) or subcutaneous (s.c.) injection. In
this study, we have investigated whether changing
the route of application will alter the eﬃcacy of 3
putative N. caninum vaccine candidates in terms of
cerebral neosporosis in mice. First, NcROP2 is a
N. caninum rhoptry protein, and pre-incubation of
parasites with antibodies directed against NcROP2
and of host cells with recombinant recNcROP2, in-
hibited host cell invasion by N. caninum tachyzoites
in vitro (Debache et al. 2008). Secondly, NcPDI, a
protein disulﬁde isomerase, is partially found within
micronemes and exposed on the surface of N. cani-
num tachyzoites, and anti-NcPDI antibodies also
impair adhesion of parasites to the host cell surface
in vitro (Naguleswaran et al. 2005). In addition, in-
hibition of NcPDI activity with a number of sulf-
hydryl blockers and the PDI inhibitor bacitracin
also have a negative inﬂuence on the interaction of
N. caninum tachyzoites with their host cells (Mu¨ller
et al. 2008). Third, NcMAG1 is located within dense
granules in tachyzoite-stage parasites, which in-
corporates into the cyst wall during tachyzoite-to-
bradyzoite stage conversion, similar to what has been
described for NcGRA2 and NcGRA7 (Vonlaufen
et al. 2004).
We here show that intra-nasal application of a
vaccine based on recNcPDI produced fundamentally
improved outcomes in terms of occurrence of clinical
signs, parasite burden and serological responses
upon challenge infection. In contrast, intra-nasal
vaccination with recNcMAG1 had a negative impact
on protection and, in the case of recNcROP2, no
substantial diﬀerences were noted.
MATERIALS AND METHODS
Unless otherwise stated, all cell culture reagents were
supplied by Gibco-BRL (Zurich, Switzerland) and
chemicals were purchased from Sigma (St Louis,
MO, USA).
Neospora caninum tachyzoite culture and
puriﬁcation
Vero cells and human foreskin ﬁbroblasts (HFF)
were routinely cultured in RPMI-1640 medium
supplemented with 10% heat-inactivated FCS, 2 mM
glutamine, 50 U of penicillin/ml and 50 mg of strep-
tomycin/ml at 37 xC/5% CO2 in tissue culture ﬂasks.
Cultures were passaged at least once per week.
N. caninum tachyzoites of the Nc1 strain (Dubey
et al. 1988) were maintained by serial passages in
Vero cells or HFF during which time FCS was re-
placed with 5% immunoglobulin G (IgG)-free horse
serum (HS). Parasites were harvested as described
previously by Hemphill et al. (1996). Infected cells
were trypsinized, washed twice in cold RPMI-1640
medium, and the resulting pellet was resuspended
in 2 ml of cold RPMI-1640 medium. Cells were
repeatedly passed through a 25 G-needle and liber-
ated tachyzoites were puriﬁed by passage through
Sephadex-G25 columns (Amersham Biosciences,
Otelﬁngen, Switzerland), previously equilibrated
with cold RPMI-1640 medium. The eluted parasites
were centrifuged at 600 g/10 min/4 xC, resupended
in cold RPMI-1640 medium, and counted in a
Neubauer chamber. Viability assessment was done
by Trypan blue exclusion, and in all experiments,
over 95% of the tachyzoites were viable.
Expression and puriﬁcation of recombinant NcPDI
(recNcPDI), NcROP2 (recNcROP2), and
NcMAG1 (recNcMAG1)
RecNcPDI was cloned into the His-tag expression
vector pET151 and expressed in Escherichia coli
BL21 Star (Invitrogen, Carlsbad, Canada) as pre-
viously described (Mu¨ller et al. 2008). RecNcROP2
was cloned into pQE-30 (Qiagen, Hilden, Germany)
as described by Debache et al. 2008, 2009), and ex-
pressed inE. coliBL21 (Novagen-EMDBiosciences,
Madison, WI, USA) harbouring the pREP4 re-
pressor plasmid (Qiagen).
The cDNA sequence coding for the NcMAG1
antigen was retrieved in GenBank under the Ac-
cession number EF580924. The deduced protein
sequence is comprised of 456 amino acids, and shares
54% identity to the homologous TgMAG1 protein
(Parmley et al. 1994). RecNcMAG1 cloning was
performed by isolation of total RNA from 3r106
puriﬁedN. caninum tachyzoites using Trizol reagent
(Invitrogen, Carlsbad, CA) according to the manu-
facturer’s instructions. First strand cDNA synthesis
reactions were performed for 1 h at 42 xC in a 20 ml
reaction mixture containing 2 mg of total RNA, 1r
ﬁrst-strand buﬀer (Invitrogen), 0.5 mM of each
dNTP (Endotell, Allschwil, Switzerland), 10 mM
dithiothreitol, 20 U of RNasin RNase inhibitor
(Promega, Madison, WI), 200 U of SuperScript II
reverse transcriptase (Invitrogen). A portion of
NcMAG1 (aa 31–394, numbering according to
the precursor protein) was ampliﬁed by RT-PCR
using MAG1-BamHI-F (5k-GGATCCCAAAGG-
GTGCCTCGCTACCC-3k) and MAG1-SmaI-R
(5k-CCCGGGTTATTCCTCCACTATTTCGT-
CCGC-3k) primers (BamHI and SmaI restriction
sites underlined). The PCR product was cloned into
pCR blunt II TOPO (Invitrogen), veriﬁed by se-
quencing and the BamHI-SmaI MAG1 insert sub-
cloned into pQE-30 (Qiagen, Hilden, Germany)
using the XL1-Blue strain (Stratagene, La Jolla, CA,
USA) as a recipient. The resulting pQE-30-MAG1
expression vector was used to transform E. coli BL21
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(Novagen-EMD Biosciences, Madison, WI) har-
bouring the pREP4 repressor plasmid (Qiagen). To
express the fusion protein, 1 l of 2r YT medium
(per litre : 16 g bacto-tryptone, 10 g bacto-yeast ex-
tract, and 5 g NaCl), pre-warmed to 37 xC and sup-
plemented with carbenicillin and kanamycin (Sigma;
100 and 25 mg/ml, respectively), was inoculated with
10 ml of an overnight starter culture grown in the
same medium. When the culture reached an OD of
0.5 at l=600 nm, isopropyl-b-D-1-thiogalactopyr-
anoside (Sigma) was added to 1 mM and expression
was carried on for 3 h at 37 xC. Bacteria were har-
vested by centrifugation and disrupted by sonication.
Puriﬁcation of recombinant His-tagged pro-
teins was performed under non-denaturing con-
ditions for recNcPDI and recNcMAG1 (Mu¨ller et al.
2008) and denaturing conditions for recNcROP2
(Debache et al. 2008), using Protino Ni-IDA
columns (Macherey-Nagel, Du¨ren, Germany), as
recommended by the manufacturer. The puriﬁed
recombinant proteins were analysed by SDS–PAGE
andWestern blotting, and the protein concentrations
were measured employing the Bio-Rad protein assay
using acetylated BSA as a standard. Following
dialysis into PBS, the recombinant proteins were
stored atx80 xC prior to use.
Immunization and challenge infection
Female C57Bl/6 mice (6 weeks of age) were pur-
chased from Charles River Laboratories (Sulzheim,
Germany) and were housed under conventional day/
night conditions according to the standards set up by
the animal welfare legislation of the Swiss Veterinary
Oﬃce. Two independent experiments, one after the
other, were carried out under the same conditions,
with virtually identical outcomes, and the results of
the second experimental trial are shown.
At the age of 8–9 weeks, mice were randomly
distributed into 10 experimental groups of 10 mice
each, and the serological status (Neospora-negative)
was checked by enzyme-linked immunosorbent
assay (ELISA). Mice in groups 1–5 were treated by
i.p. injection; mice in group 1 received 100 ml of PBS
each (i.p. infection control), group 2 received 100 ml
saponin adjuvant (SAP) at 100 mg/ml, group 3 re-
ceived 10 mg of recNcPDI in SAP, group 4 received
10 mg recNcROP2 in SAP, group 5 received 10 mg
recNcMAG1 in SAP. Mice in groups 6–10 were
treated by i.n. application through the nares, which
was performed under mild isoﬂurane anaesthesia.
Mice in group 6 received 100 ml of PBS/mouse (i.n.
infection control), group 7 received 20 ml of cholera
toxin adjuvant (CT) at 250 mg/ml, group 8 received
10 mg recNcPDI/mouse in CT, group 9 received
10 mg recROP2 in CT, group 10 received 10 mg
recNcMAG1 in CT. These procedures were carried
out on days 1, 15 and 30.We have not included a non-
vaccinated and non-treated group in these trials,
since in several similar vaccine trials carried out
to date no spontaneous deaths of mice occurred
under the conditions used (Cannas et al. 2003a, b ;
Alaeddine et al. 2005; Srinivasan et al. 2007;
Debache et al. 2008).
On day 46 all animals were challenged by i.p.
inoculation of 1r106 freshly puriﬁed N. caninum
tachyzoites. On day 74, the experiment was termi-
nated and mice were euthanized by CO2 asphy-
xiation. Those animals exhibiting clinical signs of
neosporosis (ruﬄed coat, apathy, hind limb para-
lysis) prior to day 74 were euthanized at the onset of
these signs. From each animal, blood was drawn by
cardiac puncture for serological assays, brains were
dissected under aseptic conditions and the tissue
immediately frozen atx20 xC.
Brains from the mice that were vaccinated intra-
nasally were divided into the 2 hemispheres. One
hemisphere, destined for the isolation of genomic
DNA and subsequent quantitative assessment of
parasite burden by real-time PCR (Mu¨ller et al.
2002) was immediately frozen atx20 xC. The other
hemisphere, destined for RNA isolation, cDNA
synthesis and quantitative assessment of viable para-
sites by real-time PCR on cDNA was hashed in
500 ml of QIAzolTM Lysis Reagent (Qiagen) with a
small mortar in dry-ice before being frozen at
x20 xC.
Serology
Individual blood samples including pre-immune
sera and post-immunization sera (taken prior to
infection=BI) were obtained from the tail vein, and
the ﬁnal blood samples (post-infection sera=PI)
were obtained by cardiac puncture post-euthanasia.
To evaluate the humoral immune response, samples
were analysed for N. caninum-speciﬁc immuno-
globulin G (IgG), IgG1, IgG2a and immuno-
globulin A (IgA) by ELISA, employing somatic
antigen extracts from N. caninum tachyzoites ob-
tained from cell culture (Nc-extract). Nc-extract was
prepared by subjecting tachyzoites to 3 freeze-thaw
cycles followed by sonication as described by
Alaeddine et al. (2005). Cellular debris was removed
by centrifugation, and the protein concentration in
the supernatant was measured employing the Bio-
Rad protein assay using acetylated bovine serum
albumin (BSA) as a standard (Debache et al. 2008).
To carry out the ELISAs, 96-well plates (Maxisorp,
Wiesbaden, Germany) were coated overnight at 4 xC
with 100 ml of Nc-extract (7 mg/ml), diluted in 0.1 M
NaHCO3-Na2CO3, pH 9. To block non-speciﬁc
binding of antibodies, plates were incubated for 2 h
with 200 ml of PBS containing 3% BSA and 0.2%
Tween 20. Serum samples were diluted 1 : 50 in PBS
containing 0.3% BSA/0.2% Tween 20 (BSAT) and
incubated for 2 h at 20 xC. After 3 washes with
BSAT, anti-mouse IgG conjugated to alkaline
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phosphatase (Promega, Madison, WI, USA), or goat
anti-mouse alkaline phosphatase-IgG1 or IgG2a-
conjugates (SouthernBiotech, Birmingham, USA)
and goat anti-mouse IgA-alkaline phosphatase con-
jugates (Sigma, St Louis, MO, USA) were added,
respectively, at dilution of 1 : 1000 in BSAT. Con-
jugates were incubated for 2 h at 20 xC. Following
3 washes in BSAT, the wells were subsequently
incubated with 100 ml of 1 mg/ml p-nitrophenyl-
phosphate-disodium in 10%diethanolamine contain-
ing 0.5 mMMgCl2, pH 9
.8. After allowing the colour
to develop for 30 min at 20 xC, the absorbance values
(405 nm) were read in a tunable microplate reader
(Dynatech, Embrach, Switzerland).
Quantitative real-time PCR using cerebral
genomic DNA
The conventional Neospora-speciﬁc quantitative
real-time PCR (Mu¨ller et al. 2002) from genomic
DNA was performed as previously described
(Srinivasan et al. 2007; Debache et al. 2008). Brain
DNA extraction was performed using the DNeasy1
Blood & Tissue Kit (Quiagen) (Mu¨ller et al. 2002).
The DNA concentrations in all brain samples were
determined by UV spectrophotometry, and were
adjusted to 100 ng/ml with sterile Dnase-free water.
The assessments ofN. caninum tachyzoite loads were
performed using the LightCyclerTM Instrument
(RocheDiagnostic, Basel, Switzerland). The parasite
counts were calculated by interpolation from a
standard curve with DNA equivalents from 1000,
100 and 10 parasites included in each run.
Quantitative real-time PCR using cerebral cDNA
To quantify the viable tachyzoites in brain samples,
NcGRA2-RT-PCR was performed using the corre-
sponding other hemisphere from each mouse
(Strohbusch et al. 2008a, b). Then 200 ml of chloro-
form was added to all brain samples stored in
QIAzolTM, and the upper phase, obtained after vig-
orously vortexing and centrifuging the sample for
2 min at 10 000 g, was transferred to a new tube.
Ethanol (70% v/v) was added, the sample mixed
by pipetting, and loaded onto RNeasy1 mini kit
(Qiagen) spin columns and total RNA isolation was
performed according to the standard protocol. RNA
was eluted in RNase-free water and boiled at 95 xC
for 3 min. Using the Omniscript1 Reverse Trans-
cription kit (Qiagen) and 0.5 mg random primers
(Promega, Wallisellen, Switzerland), cDNA syn-
thesis was performed according to the standard
protocol for ﬁrst-strand cDNA synthesis from
1000 ng of RNA (measured and adjusted by
NanoDropTM, Thermo Scientiﬁc, Delaware, USA).
Finally, cDNA was boiled at 95 xC for 3 min and
frozen at x80 xC prior to use. The Nc-GRA2-real
time PCR was performed according to Strohbusch
et al. (2008a, b). The parasite counts were calculated
by interpolation from a standard curve with cDNA
equivalents from 1000, 100 and 10 parasites included
in each run.
Statistics
The cerebral parasite loads in immunized mice, and
the numbers of viable tachyzoites expressing
NcGRA2 in the intra-nasally vaccinated groups,
were statistically assessed by Kruskal-Wallis mul-
tiple comparison, followed by Duncan’s multiple
range test to compare between 2 particular groups.
The diﬀerences in survival rates were checked by the
Kaplan–Meier survival method followed by log-rank
statistical test. The comparison of serological re-
sponses between the diﬀerent treatment groups was
done by ANOVA test. When comparing the samples
from the same group at diﬀerent time-points (BI and
PI), paired Student’s t-test, was used, and unpaired
Student’s t-test was used when comparing animals
from diﬀerent groups at the same time-point. All
analyses of variances were done using the NCSS
Quick Startf 2001 software.
RESULTS
Clinical signs of neosporosis caused by parasite
challenge following vaccination via intra-peritoneal
and intra-nasal routes
Following vaccination and challenge infection with
N. caninum tachyzoites, mice were carefully moni-
tored for the occurrence of clinical signs of neo-
spororis such as apathy, ruﬄed hair, loss of body
weight, rounded back and circular movements. All
mice in the 2 control groups (treated with PBS
only) succumbed to infection latest at day 21 p.i.
(Fig. 1). When only the adjuvants (either saponin or
cholera toxin) were applied, all mice died latest on
days 25 and 27, respectively. Upon immunization by
the i.p. route, recNcROP2 and recNcMAG1 pro-
vided protection in 7 and 5 out of 10 mice, respect-
ively, that did not develop any clinical signs. In
contrast, only 2 mice out of 10 that had been vacci-
nated by i.p. inoculation with recNcPDI survived
until day 28 p.i. (Fig. 1A). Intra-nasal vaccination
with recNcROP2 proved to provide a similar degree
of protection (6 out of 10 survivors) as vaccination
through the intraperitoneal route. However, the
situation was diﬀerent for the other 2 antigens. Only
1 out of 10 recNcMAG1-vaccinated mice survived
until 28 days p.i., and when recNcPDI was applied
intra-nasally, 9 out of 10 mice survived and only 1
animal succumbed to infection on day 20 (Fig. 1B).
No histological assessments were made to assess
inﬂammation within the cerebral tissues of these
mice.
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Parasite burden in brain tissues of vaccinated mice
assessed by N. caninum-speciﬁc real-time PCR
Cerebral parasite burdens in the diﬀerent treatment
groups were determined by quantitative real-time
PCR (Fig. 2). There was no signiﬁcant diﬀerence in
parasite loadbetween intra-peritoneal and intra-nasal
application of either PBS or adjuvants in the 2 control
groups. These values were comparable to respec-
tive parasite loads obtained in the recNcMAG1-
vaccinated mice. In contrast, parasite load in
recNcROP2-vaccinated mice was signiﬁcantly lower
(P<0.05) compared to the adjuvant control groups
by both, intraperitoneal and intra-nasal application.
Brain tissues of recNcPDI-vaccinated mice that
had been immunized intraperitoneally did not
exhibit any diﬀerences in parasite load compared to
the PBS-treated and saponin-treated control groups,
but brain tissues of mice that had been vaccinated
with recNcPDI through the intra-nasal route ex-
hibited values that were in the similar lower range as
for the 2 recNcROP2-vaccinated groups (P<0.01).
Thus, recNcPDI has a protective eﬀect when applied
intra-nasally, but not when applied intraperitoneally.
Quantiﬁcation of viable N. caninum tachyzoites
in infected brain hemispheres by GRA2-speciﬁc
RT real-time PCR
In order to further study the eﬀects of intra-nasal
vaccination on parasite viability, we employed a
Fig. 1. Survival curves of the diﬀerent treatment groups following experimental infection with 1r106 Neospora
caninum tachyzoites. (A) Mice were vaccinated intra-peritoneally either with PBS (control), saponin adjuvants,
recNcPDI, recNcROP2 or recNcMAG1 in saponin adjuvants. (B) Mice were vaccinated intra-nasally with PBS
(control), cholera toxin, recNcPDI, recNcROP2 or recNcMAG1 resuspended in cholera toxin. The asterisk in
(A) indicates the statistical diﬀerence (P<0.05) of the recNcPDI-vaccinated group compared with the group
vaccinated with recNcROP2 in intraperitoneally vaccinated mice. Note the high protective eﬀect (90%) achieved with
the intra-nasally applied recNcPDI vaccine in (B).
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recently developed NcGRA2-speciﬁc RT real-time
PCR (Strohbusch et al. 2008a, b), which allows
quantiﬁcation of the number of viable tachyzoites in
brain tissue samples of the diﬀerent experimental
groups. The rational behind this assay is that
NcGRA2-mRNA will only be detected when viable
parasites are present, since mRNA is rapidly de-
graded upon cell death. In contrast, genomic DNA is
inherently more stable, thus, in the case where non-
viable organisms are present in the brain tissue, these
might still be picked up by conventional real-time
PCR. We found that the numbers of viable tachy-
zoites were similar in controls and recNcROP2 and
recNcMAG1 vaccinated groups, but signiﬁcantly
decreased in mice vaccinated with recNcPDI
(P<0.05) (Fig. 3).
Humoral immune responses
By ELISA, the sera of all mice exhibited a signiﬁcant
increase (P<0.05) in IgG titres directed against the
recombinant proteins thesemice had been vaccinated
with (data not shown). Fig. 4 shows the antibody
responses following vaccination prior to infection
(BI) and post-infection prior to euthanasia (PI) as
assessed by ELISA employing crude N. caninum
extract (Nc-antigen). Prior to infection (BI), total
IgG reactive with Nc-antigen was signiﬁcantly
(P<0.05) increased in all vaccinated mice compared
to non-infected and adjuvant-control mice, no
matter whether intraperitoneal or intra-nasal vacci-
nation took place, and these levels increased signiﬁ-
cantly (P<0.05) in all animals following infection.
IgG1 and IgG2a levels remained low before infec-
tion, but also mostly increased in post-infection sera,
with few exceptions. First, in mice vaccinated in-
traperitoneally with recNcROP2, only IgG1 levels
increased signiﬁcantly (P<0.05) after infection, in-
dicating that upon infection an IgG1-biased humoral
response has taken place. In the corresponding intra-
nasally vaccinated mice, both IgG1 and IgG2a levels
increased signiﬁcantly (P<0.05) (see 1 and 1k in
Fig. 4), resulting in similar protection levels in both
cases. Secondly, mice immunized intraperitoneally
with recNcMAG1 exhibited a signiﬁcant (P<0.05)
increase of both IgG1 and IgG2a after challenge,
but in intra-nasally vaccinated mice, only IgG2a
was signiﬁcantly (P<0.05) elevated after infection,
and this was associated with a high mortality post-
challenge (see 2 and 2k in Fig. 4). Thirdly, in
recNcPDI-vaccinated mice, intraperitoneal as well
as intra-nasal immunization and subsequent chal-
lenge infection also resulted in signiﬁcant (P<0.05)
increase of both IgG1 and IgG2a, but in intra-
peritoneally vaccinated animals the values of IgG2a
were higher than those for IgG1, while in intra-
nasally vaccinated mice, IgG1 levels were higher
than those for IgG2a. The IgG1-values measured in
i.p. vaccinated and infected mice were signiﬁcantly
lower compared to i.n. vaccinated mice (P<0.05),
Fig. 2. Cerebral parasite load in the diﬀerent treatment
groups as assessed by real-time PCR (ampliﬁcation of
genomic DNA). The corresponding experimental groups
of intra-peritoneally (i.p.) and intransally (i.n.) vaccinated
mice are directly compared. Statistically signiﬁcant
diﬀerences are indicated. *=P<0.05 as compared to the
corresponding adjuvant-treated group, x=P<0.05, as
compared to the recNcPDI-treated group of
intraperitoneally vaccinated mice. Note the strongly
reduced cerebral parasite burden in the group receiving
the intra-nasally applied recNcPDI vaccine. Error bars
indicate S.D.
Fig. 3. Assessment of tachyzoite viability by detection
and quantiﬁcation of NcGRA2 transcripts in the brain
tissues of the diﬀerent treatment groups vaccinated by
intra-nasal immunization with cholera toxin adjuvant.
*=P<0.05 as compared to the cholera toxin-treated
group. Error bars indicate S.D. Note the strongly reduced
parasite viability detected in the recNcPDI vaccinated
group.
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and the IgG2a-values in i.p. vaccinated and infected
mice were signiﬁcantly higher (P<0.05) compared to
i.n. vaccinated mice (see 3 and 3k in Fig. 4).
Sera from immunized and experimentally infected
mice were also tested for the presence of IgA reactive
with Nc-antigen (Fig. 5) In all groups, IgA levels
Fig. 4. Serological analysis (total IgG, IgG1, IgG2a) of all mice in all experimental groups. Serum samples were taken
either following vaccination before infection (BI), or at the time of death following experimental infection (PI). ELISA
wells were coated with Nc-antigen. Mice were vaccinated intraperitoneally (i.p.) with antigens emulsiﬁed in saponin,
or vaccinated intra-nasally (i.n.) with antigens emulsiﬁed in cholera toxin. 1 and 1k indicate that in mice vaccinated
intraperitoneally with recNcROP2, only IgG1- levels increased signiﬁcantly after infection, while in the corresponding
intra-nasally vaccinated mice, both IgG1 and IgG2a levels increased signiﬁcantly. 2 and 2k indicate that mice
immunized intraperitoneally with recNcMAG1 exhibited a signiﬁcant increase of both IgG1 and IgG2a after challenge,
but in intra-nasally vaccinated mice, only IgG2a was signiﬁcantly elevated after infection. 3 and 3k indicate that in
recNcPDI-vaccinated mice, intraperitoneal as well as intra-nasal immunization and subsequent challenge infection also
resulted in signiﬁcant increase of both IgG1 and IgG2a, but in intraperitoneally vaccinated animals the values of IgG2a
were higher than those for IgG1, while in intra-nasally vaccinated mice, IgG1 levels were higher than those for IgG2a.
*=P<0.05 as compared to BI-sera.
Fig. 5. Detection of IgA reacting with Nc-antigen by ELISA in sera in vaccinated mice; i.p.=intraperitoneal
immunization, i.n.=intra-nasal immunization. BI=sera taken before infection, PI sera taken after infection prior to
death. Error bars indicate S.D. *=P<0.05 when comparing the diﬀerences between BI and PI sera of each group;
x=P<0.05 as compared to the cholera toxin-treated group.
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increased following infection, but highly signiﬁcant
increase (P<0.01) in IgA was only visible in sera
of mice vaccinated intra-nasally with NcROP2 and
NcPDI.
DISCUSSION
In this study, we compared the eﬃcacy of 3 dis-
tinct recombinant N. caninum antigens (NcROP2,
NcMAG1 and NcPDI) against challenge infection
with N. caninum tachyzoites in the C57BL/6 mouse
cerebral infection model. For intraperitoneal vacci-
nation, antigens were emulsiﬁed in saponin, for
intra-nasal vaccination, antigens were suspended in
cholera toxin. We here demonstrate that the eﬃcacy
of recNcROP2 vaccination was not dependent on
the route of antigen delivery, while the eﬃcacy of
recNcMAG1 deteriorated upon intra-nasal appli-
cation, and, in contrast, the eﬃcacy of recNcPDI was
highly enhanced. This study conﬁrms earlier ﬁnd-
ings on intraperitoneally applied recNcROP2 that
showed protection against both cerebral infection
and fetal infection inmice, which was associated with
a Th2-dominated immune response (Debache et al.
2008, 2009). Protection levels for NcROP2 in these
earlier studies were higher compared to the exper-
iments reported herein. On one hand, this could be
explained by the slightly diﬀerent age of the mice at
the time-point of infection. On the other hand, there
is, due to the nature of the parasite culture system,
always the possibility of a certain degree of variation
between individual experiments. In our study, we
infected mice with N. caninum tachyzoites, which
were freshly puriﬁed from in vitro-cultivated Vero
cell monolayers, chosen at the moment of their
putative highest infective stage (when most tachy-
zoites were still intracellular). Nevertheless, this
time-point can be evaluated only qualitatively and it
has been demonstrated earlier, that during extra-
cellular maintenance of N. caninum tachyzoites will
loose their infectivity within a few hours (Hemphill
et al. 1996). Thus, a very small qualitative diﬀerence
could be critical in terms of infectivity.
This study also showed that, in contrast to in-
traperitoneal delivery, intra-nasal application of
recNcPDI resulted in strongly decreased cerebral
parasite load, and in decreased numbers of viable
tachyzoites in the brain. These eﬀects were as-
sociated with an IgG1-biased humoral immune re-
sponse in intra-nasally vaccinated mice as compared
to intra-peritoneally vaccinated mice. This suggests
that recNcPDI could represent a valuable vaccine
candidate, if applied intra-nasally. Our ﬁndings con-
ﬁrm earlier studies on PDI in apicomplexan para-
sites. In human, natural IgA antibodies targeting
Toxoplasma gondii PDI have been identiﬁed (Meek
et al. 2002). Moreover, Liao et al. (2006) showed that
NcPDI was present in excretory-secretory (ES)
products, and that IgA antibodies obtained from
individual cattle cattle tear samples recognized
NcPDI. This suggested that the PDI-speciﬁc anti-
bodies may be involved in defence against para-
sites. In addition, they conﬁrmed earlier results
(Naguleswaran et al. 2005; Mu¨ller et al. 2008)
showing that PDI-speciﬁc inhibitors and NcPDI
antiserum showed inhibitory eﬀects on the growth
of N. caninum tachyzoites in vitro, indicating that
NcPDI could represent a valuable target for chemo-
therapy and/or vaccination.
To date, studies on protective immune responses
against experimentally induced neosporosis in acute
disease mouse models have produced conﬂicting re-
sults. On one hand, a number of investigations have
emphasized that the protective eﬀects of vaccines
against challenge infection are associated with the
development of a Th1-type immune response, domi-
nated by IgG2a antibody production, natural killer
(NK) cell proliferation, and increased interferon-
gamma production (Khan et al. 1997; Baszler et al.
1999; Ramamoorthy et al. 2007a, b ; Klevar et al.
2007; Ellis et al. 2008). However, others have shown
that both humoral and cell-mediated immune re-
sponses were important components of protective
immunity againstN. caninum (reviewed byHemphill
et al. 2006; Innes and Vermeulen, 2006; Williams
et al. 2007), and demonstrated that protective im-
mune responses in mice vaccinated with antigen
lysate (Baszler et al. 2000) or with puriﬁed native
NcSRS2 (Haldorson et al. 2005) were accompanied
by increased IgG1 production, implying the in-
volvement of a Th2-type response. Increased IgG1
antibody responses were also found upon vaccination
of mice with recNcMIC3 and recNcMIC1, both of
which resulted in reduced cerebral infection rates
compared to those in non-vaccinated controls
(Cannas et al. 2003a ; Alaeddine et al. 2005).Debache
et al. (2008) showed that vaccination with
recNcROP2 protected mice against acute neo-
sporosis no matter whether an IgG1-biased
(recNcROP2 emulsiﬁed in saponin adjuvants) or
IgG2a-biased (recNcROP2 emulsiﬁed in Freunds
adjuvants) humoral immune response was elici-
ted. In addition, combined recNcROP2-NcMIC1-
NcMIC3 vaccination protected mice against fetal
infection following challenge during pregnancy, in
contrast to vaccination with individual antigens, and
this eﬀect was associated with a Th2-biased immune
response associated with increased serum IgG1 re-
sponses and a high IL-4/interferon-gamma ratio
(Debache et al. 2009). However, all these studies
were carried out by applying vaccine candidates in-
traperitoneally or subcutaneously.
Another attractive route for vaccine adminis-
tration is intra-nasal application. The nasal epi-
thelium represents highly vascularized tissue with
numerous microvilli, which increase the resorbing
surface. There is little proteolytic activity in the
intra-nasal cavity, and intra-nasal immunization
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stimulates both humoral and cellular immune re-
sponses, mucosally and systemically. Thus, immune
responses can be induced also at distant sites owing
to the dissemination of eﬀector immune cells
(Porgador et al. 1997: Arakawa et al. 2003, 2005;
Hirunpetcharat et al. 1998; Pinto et al. 2004).
Finally, upon intra-nasal vaccination, the antigen
is deposited directly to the appropriate immune-
competent lymphoid tissues (Partidos et al. 2001;
Byun, 2001). This results in the activation of T-cells,
and the development of B-cells into IgA plasma cells
(Partidos et al. 2001), resulting in a potentially
eﬃcient protection against acquired infection. Intra-
nasal vaccination is, as for any immunization
regimens, enhanced by the use of an appropriate
adjuvant. We have here chosen cholera toxin pro-
duced by V. cholerae, since it is an eﬀective mucosal
adjuvant, which stimulates both Th1- and Th2-type
immune responses by co-stimulation of the antigen-
primed CD4- and CD8-T cells. In addition, the
antigen-speciﬁc CD4-T cell-mediated production
of IL-2, IL-4 and interferon-gamma is enhanced
(Debard et al. 1996).
There are diﬀerent examples of how intra-nasal
vaccination has led to protective immune responses
against other non-mucosal, penetrative pathogens,
includingPlasmodium andLeishmania (Arakawa et al.
2003, 2005; Hirunpetcharat et al. 1998; Pinto et al.
2004). In addition, intra-nasal immunization with
Toxoplasma gondii TgSAG1 and non-toxic heat-
labile enterotoxins protected mice against challenge
infection against T. gondii (Bonenfant et al. 2001),
and recently Igarashi et al. (2007) showed that intra-
nasal immunization in Balb/c mice with recombinant
TgROP2, TgGRA5 and TgGRA7 applied with
cholera toxin induced partial protection against
tissue cyst formation after oral infection with
Toxoplasma tissue cysts. Others have used intra-
nasal immunization usingT. gondiiRNA inmice and
demonstrated protection against challenge infection
(Dimier-Poisson et al. 2006). Intra-nasal vaccination
has also been applied in sheep, employing proteins
from crude extracts of T. gondii encapsulated into
poly(D, L-lactide-co-glycolide, resulting in humoral
and cell-mediated immunity (Stanley et al. 2004).
Others have demonstrated protective activity against
oocyst shedding in cats vaccinated with crude rhop-
try protein preparations via the intra-nasal route
(Garcia et al. 2007).
In contrast to T. gondii, the mouse is not a natural
host forN. caninum, and experimental infection does
not mimic the natural infection route. Thus, when
using the Nc-1 isolate, tissue cyst formation in mice
has not been observed. TheNc-1-isolate will also not
readily form tissue cysts in vitro (Vonlaufen et al.
2004; Risco-Castillo et al. 2004; Aguado-Martinez
et al. 2009), and only rarely in inbred and outbred
mice (Dubey andLindsay, 1996), thus it is very likely
that tachyzoite-to-bradyzoite stage conversion has
not taken place in these mice. Therefore, the out-
come of infection in our mouse model is most likely
related to the viability status of tachyzoite-stage
parasites. In this respect, we could demonstrate not
only a reduced overall cerebral parasite burden in
mice vaccinated intra-nasally with recNcPDI, but
also a signiﬁcantly reduced number of viable tachy-
zoites in that group.
The latter is intriguing: surprisingly, mice vacci-
nated with recNcROP2 exhibited a reduced overall
cerebral parasite burden, but not a reduced number
of viable parasites in the CNS compared with the
control groups. These relative diﬀerences between
overall parasite numbers and numbers of viable
parasites in the diﬀerent treatment groups can be
explained by the extensive proliferation of tachy-
zoites in the CNS of unvaccinated control-group
mice, which lead to an increased proportion of non-
viable parasite organisms, and also resulted in death
of all animals. In contrast, intra-nasal vaccination
with recNcROP2 and recNcPDI kept the overall
cerebral parasite burden at a lower level, but in the
case of recNcROP2-vaccinated mice, those parasites
reaching the brain tissue remained largely viable,
while in the case of recNcPDI-vaccinated mice, the
parasites could still be largely eliminated, once they
had crossed the blood-brain barrier.
It is not known why intra-nasal application of
recNcPDI induced protection, and application of the
same protein via the intra-peritoneal route did not.
Most likely though, the marked switch from an
IgG2-dominated to a more prominent IgG1 iso-
type response againstNc-antigen in intraperitoneally
versus intra-nasally vaccinated animals could be
detrimental to parasite survival, since a Th2-type
response implies a lower expression of pro-
inﬂammatory cytokines, and thus less immuno-
pathology, and a higher chance for the host to clear or
limit the infection by other immunological or
physiological means. For recNcMAG1, the opposite
eﬀect could be noted, with intra-nasally vaccinated
mice producing a signiﬁcantly increased IgG2a re-
sponse, which is indicative for a Th1-biased immune
response, and this was associated with enhanced
mortality in that group.
Clearly, further studies will be necessary to dissect
these immunological and physiological events. How-
ever, our results are in line with those reported
by Hiroi et al (1998), which showed that the nasal-
associated lymphoid tissue is characterized by a Th0
environment, that can form a Th1 and/or Th2
phenotype, but the nasal passage was considered to
be a Th2-dominant site with some Th1-type T cells,
and humoral immunity leading to IgA production.
Thus, in addition to a predominantly IgG1 response
against Nc-antigen, serum-IgA antibodies were also
signiﬁcantly elevated in the intra-nasally NcROP2
and NcPDI-vaccinated mice following challenge
infection, but not in mice vaccinated with NcMAG1.
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It is conceivable that these additional antibodies
could cause a more pronounced inhibition of parasite
host cell invasion or replication. In addition, the
close proximity of the intra-nasal cavity to the cer-
ebral tissue might also provide additional protection
against cerebral infection. All these factors, together
with, most likely, a number of unknown parameters
in the intra-nasally vaccinated mice, resulted in sig-
niﬁcantly decreased cerebral infection rates.
The fact that fewer viable tachyzoites could be
detected in the brain tissues of mice vaccinated with
recNcPDI indicates that parasites, once they have
crossed the blood-brain barrier, could still be elim-
inated.
In conclusion, this report represents the ﬁrst study
on intra-nasal vaccination against N. caninum infec-
tion in mice, and our ﬁndings suggest that recNcPDI
is a promising vaccine candidate and should be fur-
ther considered for studies where the potential of this
vaccine formulation for protection against fetal in-
fection will be investigated.
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